Poseida (PSTX) falls 3.33% on Moderate Volume September 14

Equities Staff  |

Today, Poseida Therapeutics Inc Inc’s (NASDAQ: PSTX) stock fell $0.28, accounting for a 3.33% decrease. Poseida opened at $8.32 before trading between $8.32 and $8.00 throughout Tuesday’s session. The activity saw Poseida’s market cap fall to $506,189,408 on 124,179 shares -below their 30-day average of 235,316.

About Poseida Therapeutics Inc

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core proprietary platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Its core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable Poseida Therapeutics to engineer its wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

Visit Poseida Therapeutics Inc's profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Poseida Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Poseida Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Intuit To Acquire Mailchimp for $12 Billion in Cash and Stock
Consumer Brands Association Presses White House for More Clarity on Vaccine Mandates
Freshworks Shooting for $9 Billion IPO Valuation at Top End of Filing Range
Fauci Supports COVID-19 Vaccine Mandate for All Domestic Air Travel
Jobless Claims Fall to 310,000 — Lowest in Nearly 18 Months
200 Westerners Board Qatar Airways Flight From Kabul
Pennsylvania Republican Lawmakers Launch 'Election Integrity' Investigation
President Biden and Congressional Democrats Push for Civilian Climate Corps

Market Movers

Sponsored Financial Content